Figure 3.
(a) Contingency analysis between the severity of COVID-19 and evidence of lung fibrosis during follow-up; (b) comparisons of serum IL-1β, IL17A, TNF-α, TGF-β, IL-4 and IL-6 concentrations between patients with or without lung fibrotic alterations at post-COVID-19 follow-up; (c) correlation matrix among serum biomarkers; (d) correlation plot between FVC (expressed as percentage of predicted value) and TNF-α and IL-32. ***: p< 0.0001.